ST. LOUIS, Aug. 17 /PRNewswire/ -- The Nellcor Puritan Bennett
KnightStar(TM) 335 respiratory support system, manufactured by Mallinckrodt
Inc. (NYSE: MKG), has been cleared by the U.S. Food and Drug Administration
for use in noninvasively treating patients over 30 kilograms who experience
respiratory failure in hospitals or institutional settings (MNT
classification). This action is in addition to previous indications for use
of the product, which include obstructive sleep apnea and respiratory
insufficiency in the home or institutional settings (MNS classification).
The KnightStar 335 is used for noninvasive treatment of respiratory
conditions.
"We are delighted that the 335 has been cleared for this new use," said
John Hesemann, president of Mallinckrodt's Respiratory Group. "It is an
excellent product and will provide physicians and clinicians with a new tool
for addressing respiratory failure in institutional settings."
Based in St. Louis, Mo., Mallinckrodt Inc. has three healthcare product
groups -- Imaging, Pharmaceuticals and Respiratory. The company operates in
more than 100 countries and had fiscal 1997 net sales of $1.9 billion. The
Mallinckrodt web site address is http://www.mallinckrodt.com.
SOURCE Mallinckrodt Inc.
 back to top
Related links:
http://www.mallinckrodt.com
Company News On-Call: http://www.prnewswire.com or
fax, 800-758-5804, ext. 440950
CONTACT:
Media, Peter Faur, 314-654-5234, Barbara
Abbett, 314-654-5230, or e-mail, Communications@mkg.com; or
Investors, Barbara Gould, 314-654-3190, or e-mail, Invest@mkg.com
|
